Member Info for gtc1507

Fusion is pivoting from a traditional CRO to a high-value tech platform company. Years of R&D are maturing now:

• ✅ OptiMAL validated by US National Cancer Institute – platform works, now testing how well

• ✅ OptiPhage project completed with a global antibody leader – they now hold exclusive licence option and are in the window for evaluating whether to take it.

• ✅ Strategic shift to platform licensing and recurring revenue is underway but underpinned by growing bread and butter business model.

• ✅ US patent for OptiMAL has been allowed – just awaiting formal grant. This locks in core IP at a critical moment

• ✅ Market cap just ~£6m – massively below peer platform plays

• ✅ Step-change in revenue could land any day via licensing, milestones, or major deals

Peer Platform Comparables:

• 🔹 Absci Corp (NASDAQ: ABSI) – AI + synthetic biology antibody platform | Market Cap: $300m+

• 🔹 Evaxion Biotech (NASDAQ: EVAX) – AI-immunology platforms, early-stage licensing | Market Cap: $20–30m

• 🔹 FJBio (private) – mamallian display antibody discovery, not public but gaining strategic traction - valued around €900m

Fusion has validated IP, commercial traction, and platform upside — all at a fraction of the valuation. The market is asleep. The rerate could be violent. DYOR

Looks like a few others taking the opportunity - some decent buys showing up now at 6.6, MMs showing they red!

My sense from the investor meet is the more to come isn’t even refeeence to the patents. Some really exciting stuff. Also the window for their optiphage client to decide on exclusively taking on that licence is counting down to closing so he very excited if they announce a licence agreement on that!

Morning all! Wonder will people have digested last week over the weekend and decided to come in!

Very strong presentation from Adrian, feels like we’re on the cusp of something special in the coming months, “step-changes” ahead and FAB news coming out of the USPTO! Exciting times to come

Feels like they’re right wheee they need to be at the right time. On track and primed for a really exciting time! Very happy to sit and let them do their thing and spoils should speak for themselves soon!

Obviously great that the tech works but I hadn’t quite picked up the importance of the fact NCI were able to use it. Adrian laboured the point that this demonstrates the tech can be transferred to other people’s labs, clients, partners etc and therefore they have successfully demonstrated in a licencing scenario that it can be used by others!

Adrian’s latest investor call was full of intent and clarity:

🔹 “We now know Optimal works.”

🔹 “No one comes even 1% close to our scale of mammalian display.”

🔹 “This puts us exactly on track for where we wanted to be.”

🔹 “We’re looking at step changes, not just incremental advancements.”

🔹 “I’ve got more up my sleeve than just my arms.”

💡 Fusion yesterday confirmed:

– Optimal works and was able to be used successfully by the US National Cancer Institute

– Patent allowance now secured in the US

– No further raise needed for working capital

– Breakeven within reach

Fusion is clearly now extremely well positioned to commercialise Optimal as a high-value, license-ready platform, with a CEO clearly aligned to delivering that potential.

Exciting times

Was a fantastic presentation, explained a lot. Also glad they released the RNS today. It was publicly available information that had the potential to move the share price so right to release it and not wait until the patent granted. Very very enticing time - step change territory!

There we go!

Https://youtu.be/h370dmBSjxM?feature=shared

Outstanding presentation real confidence tbh. It’ll be up soon hopefully

There is a slight nuance in the wording he used. He said that he would update the market as and when patterns are granted. The pattern has been “allowed “in the US my understanding is that it will move to be “granted” as soon as the fee is paidand then it’s issued .perhaps we might get the RS at that stage.

“ It can be licenced; it can be run in other labs; we’re not the limit for capacity not going to constrain the update and therefore the commercial value of it”

A quick check of the patent application number on thenUS patent office website says applicant is fusion antibodies

Presentation at 11:30! Hopefully get some good updates on Optimal!

Https://x.com/thesaintcharts/status/1924343007912014299?s=12

Great analysis! Strong

Hopefully the rally continues as we move to Thursday’s update presentation! Very interested to see what we hear about Optimal, NCI and the grants

Great day moving back and closing at placing price.

Important week next week with Thursday a great opportunity for them to sell the reasons for the recent raise and their growth prospects.

Yeah I see as a positive, they’re nearing the end of validation, makes sense for them to have NCI validation complete to then charge a premium. Time diff to me means we’re closer to an outcome

Https://x.com/afzalvalli/status/1923029485500194998?s=46

A q I asked has been picked up by the folks on X, there is already partners in discussions about Optimal!! Could be cracking news to land the validation and then a contracf